Details of the Drug

General Information of Drug (ID: DM5FSJA)

Drug Name

Glimepiride

Synonyms

Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1], [2]

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

490.6

Topological Polar Surface Area (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The total body clearance of drug is 52.1 +/- 16.0 mL/min [6]
Elimination: Following oral administration of glimepiride in healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days, with M1 and M2 accounting for 80-90% of the total radioactivity recovered in the urine [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 8 hours [8]
Metabolism: The drug is metabolized via the hepatic [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.233 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.005% [10]
Vd: The volume of distribution (Vd) of drug is 8.8 L [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0012 mg/mL [4]

Chemical Identifiers

Formula: C24H34N4O5S
IUPAC Name: 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
Canonical SMILES: CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
InChI: InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
InChIKey: WIGIZIANZCJQQY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3476
ChEBI ID: CHEBI:5383
CAS Number: 261361-60-8
DrugBank ID: DB00222
TTD ID: D0B2GI
VARIDT ID: DR00158
INTEDE ID: DR0777
ACDINA ID: D00302

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Blocker	[11]
ATP-binding cassette transporter C9 (ABCC9)	TTEF5MJ	ABCC9_HUMAN	Blocker	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Bile salt export pump (ABCB11)	DTJ0EW4	ABCBB_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	6.51E-01	0.02	0.06
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	8.46E-01	0.02	0.22
Bile salt export pump (ABCB11)	DTP	BSEP	3.72E-02	8.26E-02	6.55E-01
Bile salt export pump (ABCB11)	DTP	BSEP	2.15E-02	-1.67E-02	-6.13E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.33E-02	5.59E-02	2.99E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	5.65E-03	-7.28E-02	-1.24E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Glimepiride

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Glimepiride caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[38]
-----------

Coadministration of a Drug Treating the Disease Different from Glimepiride (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Glimepiride caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[39]
Oxandrolone	DMU9MYJ	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Oxandrolone.	Alcoholic liver disease [DB94]	[40]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Glimepiride caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[40]
Clarithromycin	DM4M1SG	Moderate	Increased plasma concentration of Glimepiride and Clarithromycin due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[41]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[40]
Chloramphenicol	DMFXEWT	Moderate	Increased plasma concentration of Glimepiride and Chloramphenicol due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[42]
Linezolid	DMGFPU2	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Linezolid.	Bacterial infection [1A00-1C4Z]	[40]
Nitazoxanide	DMOWLVG	Moderate	Increased plasma concentration of Glimepiride and Nitazoxanide due to competitive binding of plasma proteins.	Bowel habit change [ME05]	[43]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Glimepiride caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[40]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[40]
Phenylbutazone	DMAYL0T	Moderate	Decreased renal excretion of Glimepiride caused by Phenylbutazone.	Chronic pain [MG30]	[39]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Ketoprofen.	Chronic pain [MG30]	[40]
Ardeparin	DMYRX8B	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Ardeparin.	Coronary thrombosis [BA43]	[40]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Glimepiride caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[45]
Aminoglutethimide	DMWFHMZ	Minor	Increased metabolism of Glimepiride caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[46]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Glimepiride caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[47]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Glimepiride caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[48]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Glimepiride caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[49]
Aprepitant	DM053KT	Moderate	Increased metabolism of Glimepiride caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[50]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sertraline.	Depression [6A70-6A7Z]	[40]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fluoxetine.	Depression [6A70-6A7Z]	[40]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Vilazodone.	Depression [6A70-6A7Z]	[40]
Paroxetine	DM5PVQE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Paroxetine.	Depression [6A70-6A7Z]	[40]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Selegiline.	Depression [6A70-6A7Z]	[40]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Vortioxetine.	Depression [6A70-6A7Z]	[40]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Isocarboxazid.	Depression [6A70-6A7Z]	[40]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Escitalopram.	Depression [6A70-6A7Z]	[40]
Tranylcypromine	DMGB5RE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Tranylcypromine.	Depression [6A70-6A7Z]	[40]
Phenelzine	DMHIDUE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Phenelzine.	Depression [6A70-6A7Z]	[40]
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and PMID28454500-Compound-96.	Discovery agent [N.A.]	[40]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and PMID28870136-Compound-49.	Discovery agent [N.A.]	[40]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Mefenamic acid.	Female pelvic pain [GA34]	[40]
Miconazole	DMPMYE8	Major	Decreased metabolism of Glimepiride caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[40]
Omeprazole	DM471KJ	Minor	Decreased metabolism of Glimepiride caused by Omeprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[51]
Nizatidine	DMGFV3Z	Moderate	Decreased absorption of Glimepiride due to altered gastric pH caused by Nizatidine.	Gastro-oesophageal reflux disease [DA22]	[52]
Cimetidine	DMH61ZB	Moderate	Decreased absorption of Glimepiride due to altered gastric pH caused by Cimetidine.	Gastro-oesophageal reflux disease [DA22]	[52]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[40]
Sulfinpyrazone	DMEV954	Moderate	Decreased metabolism of Glimepiride caused by Sulfinpyrazone.	Gout [FA25]	[39]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Glimepiride caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[53]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Glimepiride caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[54]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Glimepiride caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[40]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[40]
Clofibrate	DMPC1J7	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Clofibrate.	Hyper-lipoproteinaemia [5C80]	[40]
Moexipril	DM26E4B	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Moexipril.	Hypertension [BA00-BA04]	[40]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Captopril.	Hypertension [BA00-BA04]	[40]
Trandolapril	DM4L6EU	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Trandolapril.	Hypertension [BA00-BA04]	[40]
Methyldopa	DM5I621	Minor	Decreased metabolism of Glimepiride caused by Methyldopa.	Hypertension [BA00-BA04]	[56]
Fosinopril	DM9NJ52	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fosinopril.	Hypertension [BA00-BA04]	[40]
Benazepril	DMH1M9B	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Benazepril.	Hypertension [BA00-BA04]	[40]
Enalapril	DMNFUZR	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Enalapril.	Hypertension [BA00-BA04]	[40]
Perindopril	DMOPZDT	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Perindopril.	Hypertension [BA00-BA04]	[40]
Quinapril	DMR8H31	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Quinapril.	Hypertension [BA00-BA04]	[40]
Lisinopril	DMUOK4C	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Lisinopril.	Hypertension [BA00-BA04]	[40]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[40]
Balsalazide	DMO091F	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Balsalazide.	Indeterminate colitis [DD72]	[40]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[57]
Testosterone	DM7HUNW	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Testosterone.	Low bone mass disorder [FB83]	[40]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Glimepiride and Porfimer Sodium.	Lung cancer [2C25]	[58]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Glimepiride caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[59]
Chloroquine	DMSI5CB	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Chloroquine.	Malaria [1F40-1F45]	[40]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Hydroxychloroquine.	Malaria [1F40-1F45]	[40]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulphadoxine.	Malaria [1F40-1F45]	[40]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Glimepiride caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[59]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Glimepiride caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[60]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[40]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Glimepiride caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[53]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Glimepiride and Methoxsalen.	Mycosis fungoides [2B01]	[59]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Glimepiride caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[61]
Nalmefene	DM4YWCZ	Moderate	Increased plasma concentration of Glimepiride and Nalmefene due to competitive binding of plasma proteins.	Opioid use disorder [6C43]	[42]
Rofecoxib	DM3P5DA	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Rofecoxib.	Osteoarthritis [FA00-FA05]	[40]
Valdecoxib	DMAY7H4	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Valdecoxib.	Osteoarthritis [FA00-FA05]	[40]
Diclofenac	DMPIHLS	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Diclofenac.	Osteoarthritis [FA00-FA05]	[40]
Naproxen	DMZ5RGV	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Naproxen.	Osteoarthritis [FA00-FA05]	[40]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Glimepiride caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[62]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Dextropropoxyphene.	Pain [MG30-MG3Z]	[57]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Aspirin.	Pain [MG30-MG3Z]	[57]
Etodolac	DM6WJO9	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Etodolac.	Pain [MG30-MG3Z]	[40]
Diflunisal	DM7EN8I	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Diflunisal.	Pain [MG30-MG3Z]	[40]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Ibuprofen.	Pain [MG30-MG3Z]	[40]
Nabumetone	DMAT2XH	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Nabumetone.	Pain [MG30-MG3Z]	[40]
Piroxicam	DMTK234	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Piroxicam.	Pain [MG30-MG3Z]	[40]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Rasagiline.	Parkinsonism [8A00]	[40]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Glimepiride due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[52]
Esomeprazole	DM7BN0X	Minor	Decreased metabolism of Glimepiride caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[51]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Glimepiride due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[52]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[40]
Ketorolac	DMI4EL5	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Ketorolac.	Postoperative inflammation [1A00-CA43]	[40]
Bromfenac	DMKB79O	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Bromfenac.	Postoperative inflammation [1A00-CA43]	[40]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Glimepiride caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[63]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Glimepiride and Verteporfin.	Psoriasis [EA90]	[39]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Glimepiride caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[64]
Sulfadiazine	DMTW3R8	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulfadiazine.	Rheumatic fever [1B40]	[40]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Salsalate.	Rheumatoid arthritis [FA20]	[40]
Sulindac	DM2QHZU	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulindac.	Rheumatoid arthritis [FA20]	[40]
Celecoxib	DM6LOQU	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Celecoxib.	Rheumatoid arthritis [FA20]	[40]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Oxaprozin.	Rheumatoid arthritis [FA20]	[40]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Flurbiprofen.	Rheumatoid arthritis [FA20]	[40]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulfasalazine.	Rheumatoid arthritis [FA20]	[40]
Fenoprofen	DML5VQ0	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Fenoprofen.	Rheumatoid arthritis [FA20]	[40]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Glimepiride caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[65]
Indomethacin	DMSC4A7	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Indomethacin.	Rheumatoid arthritis [FA20]	[40]
Tolmetin	DMWUIJE	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Tolmetin.	Rheumatoid arthritis [FA20]	[40]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[57]
Cyclophosphamide	DM4O2Z7	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[40]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[40]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[40]
Warfarin	DMJYCVW	Moderate	Increased plasma concentration of Glimepiride and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[42]
Clopidogrel	DMOL54H	Minor	Decreased metabolism of Glimepiride caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[66]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[40]
Mesalazine	DMOL5IU	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Mesalazine.	Ulcerative colitis [DD71]	[57]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Olsalazine.	Ulcerative colitis [DD71]	[40]
Sulfamethizole	DMGCHDS	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulfamethizole.	Urinary tract infection [GC08]	[40]
Sulfisoxazole	DMXLT8C	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Sulfisoxazole.	Urinary tract infection [GC08]	[40]
Disopyramide	DM5SYZP	Moderate	Increased risk of hypoglycemia by the combination of Glimepiride and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[40]
-----------


⏷ Show the Full List of 116 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Glimepiride 3 mg tablet	3 mg	Oral Tablet	Oral
Glimepiride 6 mg tablet	6 mg	Oral Tablet	Oral
Glimepiride 2 mg tablet	2 mg	Oral Tablet	Oral
Glimepiride 8 mg tablet	8 mg	Oral Tablet	Oral
Glimepiride 4 mg tablet	4 mg	Oral Tablet	Oral
Glimepiride 1 mg tablet	1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6820).
2	Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus. Orv Hetil. 2007 Dec 9;148(49):2331-5.
3	Basit A, Riaz M, Fawwad A: Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012;8:463-72. doi: 10.2147/HIV.S33194. Epub 2012 Aug 15.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Amaryl (glimepiride) Product Monograph - Sanofi in Canada
7	AMARYL (glimepiride) FDA Label
8	Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015 Aug 12;11(4):840-8. doi: 10.5114/aoms.2015.53304. Epub 2015 Aug 11.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
12	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
13	Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006 May;72(2):148-54.
14	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
15	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
16	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
17	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
18	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
19	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
20	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
21	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
22	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
23	Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
24	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
25	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90.
26	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
27	A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
28	BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.
29	Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes
30	Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68.
31	The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55.
32	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
33	Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
34	Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
35	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7.
36	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).
38	Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
41	Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
42	Product Information. Amaryl (glimepiride). Hoechst Marion-Roussel Inc, Kansas City, MO.
43	Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
44	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
46	Kvinssland S, Lonning PE, Ueland PM "Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects." Breast Cancer Res Treat 7 (1986): s73-6. [PMID: 2943339]
47	Cerner Multum, Inc. "Canadian Product Information.".
48	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
49	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
50	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
51	Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
52	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
53	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
54	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
55	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56	Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
57	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
58	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
59	Cerner Multum, Inc. "Australian Product Information.".
60	Canadian Pharmacists Association.
61	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
62	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
63	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
64	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
65	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
66	Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.